🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

23 results for “Tyra” Clear

  1. -, COLESTYRAMINE , AUBAGIO 14 mg film-coated tablets, -, Matched Placebo to Test, Tolebrutinib, Matched Placebo for Comparator Teriflunomide

    Sanofi Pharma Bristol-Myers Squibb

    Nervous system diseases

    phase 3 small molecule active

    1 trial

  2. -, Sodium butyrate 1,1 g/L sol prep

    ISTA Pharma Limited

    Hirschsprung's disease

    phase 3 small molecule active

    1 trial

  3. AUBAGIO 14 mg film-coated tablets, COLESTYRAMINE , -, Matched Placebo to Test, Matched Placebo for Comparator Teriflunomide, Tolebrutinib, -

    Sanofi Pharma Bristol-Myers Squibb

    Nervous system diseases

    phase 3 small molecule active

    1 trial

  4. AUBAGIO 14 mg film-coated tablets, Frexalimab, AUBAGIO 14 mg film-coated tablets, AUBAGIO 14 mg film-coated tablets, COLESTYRAMINE , AUBAGIO 14 mg film-coated tablets, Matched placebo for comparator teriflunomide, AUBAGIO 14 mg film-coated tablets, Matched placebo for test product frexalimab

    Sanofi Pharma Bristol-Myers Squibb

    multiple sclerosis

    phase 3 small molecule active

    1 trial

  5. LOU064, COLESTYRAMINE , TERIFLUNOMIDE, Placebo to teriflunomide 14 mg capsule, hard, Placebo to Remibrutinib (LOU064) 100 mg film-coated tablet, MEDICINAL CHARCOAL

    Novartis Ophthalmics Europe

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  6. LOU064, Placebo to teriflunomide 14 mg capsule, hard, COLESTYRAMINE , Placebo to Remibrutinib (LOU064) 100 mg film-coated tablet, TERIFLUNOMIDE, MEDICINAL CHARCOAL

    Novartis Ophthalmics Europe

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  7. METYRAPONE ESTEVE 250 mg, capsule molle, Placebo of metyrapon 250 mg

    Pari Pharma GmbH

    Primary Bilateral Macronodular Adrenal Hyperplasia causing moderate Cushing Syndrome (Mild autonomous Cortisol secretion)

    phase 3 small molecule active

    1 trial

  8. A Multicenter, Open-label Phase 1/2 Study of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF-301)

    Tyra Biosciences

    Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations

    phase 2 other active

    1 trial

  9. A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants with FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

    Tyra Biosciences

    Non-muscle invasive bladder cancer (NMIBC)

    phase 2 other active

    1 trial

  10. Dabogratinib (TYRA-300) 60mg

    Tyra Biosciences

    Low Grade Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  11. Sodium Phenylbutyrate

    Ultragenyx UK Limited

    Argininosuccinic Aciduria

    phase 2 small molecule completed

    1 trial

  12. Sodium phenylbutyrate

    ZEVRA THERAPEUTICS, INC.

    Medium-chain Acyl-CoA Dehydrogenase Deficiency

    phase 2 small molecule active

    1 trial

  13. TYRA-300

    Tyra Biosciences

    Locally Advanced Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  14. TYRA-300 0.125 mg/kg

    Tyra Biosciences

    Achondroplasia

    phase 2 small molecule active

    1 trial

  15. TYRA-300 60mg

    Tyra Biosciences

    Low-grade NMIBC

    phase 2 small molecule active

    1 trial

  16. arginine butyrate

    Ultragenyx UK Limited

    Beta-Thalassemia

    phase 2 small molecule completed

    1 trial

  17. Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]

    S.L

    STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder

    phase 1 small molecule active

    1 trial

  18. Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles

    Tyra Biosciences

    Locally Advanced Cholangiocarcinoma

    phase 1 small molecule active

    1 trial

  19. Sodium phenylbutyrate

    ZEVRA THERAPEUTICS, INC.

    Combined D,L-2-hydroxyglutaric Aciduria

    phase 1 small molecule active

    1 trial

  20. TYRA-300-B01

    Tyra Biosciences

    Healthy

    phase 1 small molecule active

    1 trial

  21. TYRA-430

    Tyra Biosciences

    Metastatic Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

  22. metyrapone & oxazepam

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 1 small molecule completed

    1 trial

  23. High-amylose maize starch+acetate/butyrate

    United Therapeutics Europe Ltd

    Aerobic Endurance

    other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources